Pub. Date : 2016 May 10
PMID : 26945977
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize their apoptotic response to DNA damage agent doxorubicin (DOX). | Doxorubicin | epidermal growth factor receptor | Homo sapiens |
| 2 | Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize their apoptotic response to DNA damage agent doxorubicin (DOX). | Doxorubicin | epidermal growth factor receptor | Homo sapiens |
| 3 | Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize their apoptotic response to DNA damage agent doxorubicin (DOX). | Doxorubicin | epidermal growth factor receptor | Homo sapiens |
| 4 | Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize their apoptotic response to DNA damage agent doxorubicin (DOX). | Doxorubicin | epidermal growth factor receptor | Homo sapiens |
| 5 | Due to the pretreatment and time-staggered inhibition of EGFR with erlotinib and the enhanced intracellular release of DOX to the nucleus, the maximized synergistic cell killing effect was achieved. | Doxorubicin | epidermal growth factor receptor | Homo sapiens |